
95 % of all the tested drug substances for the treatment of ailments connected to the central nervous system fail because they are unable to pass through the blood-brain barrier.
That’s why the new research from the Department of Pharmaceutics and Analytical Chemistry at Copenhagen University could turn out to be highly significant for the pharmaceutical industry. Danish companies Lundbeck and Neurosearch are among the companies working with the development of pharmaceuticals for diseases in the central nervous system.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app